Progress and challenges in the adjuvant treatment of stage II and III colon cancers

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst.96(19), 1420–1425 (2004).
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350(23), 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol.6(10), 1653–1664 (1988).
   PubMed Web of Science ®Google Scholar
• Kovach JS, Svingen PA, Schaid DJ. Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase. J. Natl Cancer Inst.84(7), 515–519 (1992).
   PubMedGoogle Scholar
• No authors listed. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA264(11), 1444–1450 (1990).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med.322(6), 352–358 (1990).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Fisher B, Rockette H et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J. Natl Cancer Inst.80(1), 30–36 (1988).
   PubMed Web of Science ®Google Scholar
• Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J. Natl Cancer Inst.96(15), 1128–1132 (2004).
   PubMedGoogle Scholar
• Boice JD Jr, Greene MH, Killen JY Jr et al. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N. Engl. J. Med.309(18), 1079–1084 (1983).
   PubMed Web of Science ®Google Scholar
• O’Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J. Clin. Oncol.15(1), 246–250 (1997).
   PubMed Web of Science ®Google Scholar
• O’Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J. Clin. Oncol.16(1), 295–300 (1998).
   PubMed Web of Science ®Google Scholar
• QUASAR Collaborative Group. Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet355(9215), 1588–1596 (2000).
   PubMed Web of Science ®Google Scholar
• Porschen R, Bermann A, Loffler T et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J. Clin. Oncol.19(6), 1787–1794 (2001).
   PubMedGoogle Scholar
• Arkenau HT, Bermann A, Rettig K, Strohmeyer G, Porschen R. 5-fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann. Oncol.14(3), 395–399 (2003).
   PubMed Web of Science ®Google Scholar
• Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br. J. Cancer85(10), 1437–1443 (2001).
   PubMed Web of Science ®Google Scholar
• Di Costanzo F, Sobrero A, Gasperoni S et al. Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann. Oncol.14(9), 1365–1372 (2003).
   PubMedGoogle Scholar
• Link KH, Kornmann M, Staib L et al. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Ann. Surg.242(2), 178–187 (2005).
   PubMedGoogle Scholar
• Schippinger W, Jagoditsch M, Sorre C et al. A prospective randomised trial to study the role of levamisole and interferon α in an adjuvant therapy with 5-FU for stage III colon cancer. Br. J. Cancer92(9), 1655–1662 (2005).
   PubMedGoogle Scholar
• Sobrero A, Frassineti G, Falcone A et al. Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer. Br. J. Cancer92(1), 24–29 (2005).
   PubMedGoogle Scholar
• Haller DG, Catalano PJ, Macdonald JS et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J. Clin. Oncol.23(34), 8671–8678 (2005).
   PubMed Web of Science ®Google Scholar
• De Placido S, Lopez M, Carlomagno C et al. Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, Phase III study. Br. J. Cancer93(8), 896–904 (2005).
   PubMedGoogle Scholar
• O’Connell MJ, Sargent DJ, Windschitl HE et al. Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Clin. Colorectal Cancer6(2), 133–139 (2006).
   PubMedGoogle Scholar
• No authors listed. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J. Clin. Oncol.16(1), 301–308 (1998).
   PubMed Web of Science ®Google Scholar
• Carrato A, Köhne C, Bedenne L et al. Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. J. Clin. Oncol.24(Suppl. 18), (2006) (Abstract 3563).
   PubMedGoogle Scholar
• Chau I, Norman AR, Cunningham D et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann. Oncol.16(4), 549–557 (2005).
   PubMed Web of Science ®Google Scholar
• Poplin EA, Benedetti JK, Estes NC et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J. Clin. Oncol.23(9), 1819–1825 (2005).
   PubMed Web of Science ®Google Scholar
• Andre T, Colin P, Louvet C et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J. Clin. Oncol.21(15), 2896–2903 (2003).
   PubMed Web of Science ®Google Scholar
• Andre T, Quinaux E, Louvet C et al. Updated results at 6 year of the GERCOR C96.1 Phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients. J. Clin. Oncol.23(Suppl. 16), (2005) (Abstract 3522).
   Google Scholar
• van Cutsem E, Labianca R, Hossfeld D et al. Randomized Phase III trial conparing infused irintecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/DA (F) in stage III colon cancer patients (pts). J. Clin. Oncol.23(Suppl. 16), S3 (2005) (Abstract LBA8).
   Google Scholar
• Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase III trials. Br. J. Cancer90(6), 1190–1197 (2004).
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med.352(26), 2696–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br. J. Cancer94(8), 1122–1129 (2006).
   PubMed Web of Science ®Google Scholar
• Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol.24(13), 2059–2064 (2006).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18(16), 2938–2947 (2000).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343(13), 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Ychou M, Raoul JL, Douillard JY et al. A Phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J. Clin. Oncol.23(Suppl. 16), S246 (2005) (Abstract 3502).
   Google Scholar
• Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol.25(23), 3456–3461 (2007).
   PubMed Web of Science ®Google Scholar
• Kuebler JP, Wieand HS, O’Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol.25(16), 2198–2204 (2007).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J. Clin. Oncol.25(Suppl.18), 4007 (2007).
   Web of Science ®Google Scholar
• Green E, Sargent DJ, Goldberg RM, Grothey A. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741. Presented at: Program and Proceedings of the 2005 Gastrointestinal Cancer Symposium. Hollywood, FL, USA. 27–29 January 2005 (Abstract 182).
   Google Scholar
• Land SR, Kopec JA, Cecchini RS et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J. Clin. Oncol.25(16), 2205–2211 (2007).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803).J. Clin. Oncol.22(Suppl. 14), (2004) (Abstract 2500).
   Google Scholar
• Peeters M, Van Cutsem E, Siena S et al. A Phase III, multicenter, randomized controlled tial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Presented at: Proceedings of the 97th American Association for Cancer Research Annual Meeting. 1–5 April 2006, Washington, DC, USA (2006) (Abstract CP-1).
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Levy D, O’Dwyer PJ et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): updated results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. Presented at: The 2004 Gastrointestinal Cancers Symposium. 22–24 January 2004, San Francisco, CA, USA (Abstract 289).
   Google Scholar
• Riethmuller G, Schneider-Gadicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’C colorectal carcinoma. German Cancer Aid 17–1A Study Group. Lancet343(8907), 1177–1183 (1994).
   PubMed Web of Science ®Google Scholar
• Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet360(9334), 671–677 (2002).
   PubMed Web of Science ®Google Scholar
• Fields AL, Keller AM, Schwartzberg L et al. Edrecolomab (17–1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised north american Phase III study. Proc. Am. Soc. Clin. Oncol.21, (2002) (Abstract 508).
   Google Scholar
• Gray RG, Barnwell J, Hills R et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. J. Clin. Oncol.22(Suppl. 14), 3501 (2004).
   Google Scholar
• Quasar Collaborative Group, Gray R, Barnwell J et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet370(9604), 2020–2029 (2007).
   PubMed Web of Science ®Google Scholar
• Schippinger W, Samonigg H, Schaberl-Moser R et al. A prospective randomised Phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br. J. Cancer97(8), 1021–1027 (2007).
   PubMed Web of Science ®Google Scholar
• No authors listed. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J. Clin. Oncol.17(5), 1356–1363 (1999).
   Google Scholar
• Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J. Clin. Oncol.22(16), 3395–3407 (2004).
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol.22(10), 1797–1806 (2004).
   PubMed Web of Science ®Google Scholar
• Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol.17(5), 1349–1355 (1999).
   PubMed Web of Science ®Google Scholar
• Benson AB III, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol.22(16), 3408–3419 (2004).
   PubMed Web of Science ®Google Scholar
• Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann. Surg. Oncol.10(1), 65–71 (2003).
   PubMed Web of Science ®Google Scholar
• Tepper JE, O’Connell MJ, Niedzwiecki D et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J. Clin. Oncol.19(1), 157–163 (2001).
   PubMed Web of Science ®Google Scholar
• Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup trial INT-0089. J. Clin. Oncol.21(15), 2912–2919 (2003).
   PubMed Web of Science ®Google Scholar
• Berger AC, Sigurdson ER, LeVoyer T et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J. Clin. Oncol.23(34), 8706–8712 (2005).
   PubMed Web of Science ®Google Scholar
• Hershman D, Hall MJ, Wang X et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer107(11), 2581–2588 (2006).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Wickerham DL et al. Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J. Clin. Oncol.8(9), 1466–1475 (1990).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J. Clin. Oncol.11(10), 1879–1887 (1993).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol.17(11), 3553–3559 (1999).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Bryant J, Smith R et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon α-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J. Natl Cancer Inst.90(23), 1810–1816 (1998).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wieand S, Lembersky B et al. A Phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06. J. Clin. Oncol.22(Suppl. 14), (2004) (Abstract 3508).
   Google Scholar
• Wolmark N, Wieand S, Kuebler JP, Colangelo L, Smith R. A Phase III trial comparing FULV to FULV plus oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. J. Clin. Oncol.23(Suppl. 16), S246 (2005) (Abstract LBA 3500).
   Google Scholar
• Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol.23(34), 8664–8670 (2005).
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Patiyil S, Yothers G et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J. Clin. Oncol.25(29), 4569–4574 (2007).
   PubMed Web of Science ®Google Scholar
• Sargent DJ, for the Adjuvant Colon Cancer Endpoints (ACCENT) Group. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: lessons from the 20,800-patient (pt) ACCENT dataset. J. Clin. Oncol.25(Suppl. 18), 4008 (2007).
   Google Scholar
• Chua YJ, Sargent D, Cunningham D. Definition of disease-free survival: this is my truth-show me yours. Ann. Oncol.16(11), 1719–1721 (2005).
   PubMed Web of Science ®Google Scholar
• Punt CJ, Buyse M, Kohne CH et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J. Natl Cancer Inst.99(13), 998–1003 (2007).
   PubMed Web of Science ®Google Scholar
• O’Connell MJ, for the Adjuvant Colon Cancer Endpoints (ACCENT) Group. Survival following recurrence in patients with adjuvant colon cancer: Findings from the 20,800-patient ACCENT dataset. J. Clin. Oncol.25(Suppl. 18), 4009 (2007).
   PubMedGoogle Scholar